Evonik's November Reckoning: A US Shopping List, a €22.15 Bid, and the Case for Standing Alone

Evonik investors face a two-track question this autumn, and the two tracks are not as separate as they first appear. One is whether the specialty chemicals group can buy its way into a stronger standalone position, with US specialty chemicals player Ashland in its sights. The other is whether it will end up inside BASF at all. The next hard data point on the operating side arrives with the third-quarter 2026 report scheduled for 3 November.

According to Handelsblatt, Evonik has spent months scouting larger acquisitions outside Europe and has zeroed in on Ashland. Perella Weinberg Partners and JPMorgan have been retained to hunt for targets. No purchase decision follows from that mandate, and neither Evonik nor the banks would comment on the deliberations. Crucially, the review predates the BASF interest that later became public; people close to the company describe it as no defensive manoeuvre. That chronology matters, because it frames the US move as a long-standing strategic track rather than a reaction to a suitor at the door.

A US Deal Would Be Judged on Price, Not Logic

Ashland would fit Evonik's portfolio in cosmetic ingredients and specialty additives, and a purchase could reduce the group's dependence on the European market. The industrial rationale is easy to follow. The valuation question is not: at what price would that benefit actually pay off for Evonik shareholders?

Ashland's rising share price is seen as a material risk, the report says. Advent, Apollo and Carlyle have also made contact, and Ashland is hunting a buyer under pressure from Ancora. More interested parties could narrow the room for a bargain, though whether a genuine bidding contest emerges remains open. Set against that is the BASF offer of EUR 22.15 per share, which Evonik rejected as too low. That figure is a negotiating anchor, not a guaranteed payout.

Both routes deserve the same yardstick: economic value for shareholders, not strategic size or independence for its own sake. A strategically neat acquisition can still be financially unattractive. If the price for Ashland climbs too far, Evonik could pay upfront for the very benefit it hopes to capture — and the presence of rival bidders makes that risk live without pre-judging an expensive outcome.

The Bid, the Books, and Kamieth's Caveat

BASF chief executive Markus Kamieth has said he is open to talks but not at any price. A combination would raise antitrust questions alongside the valuation debate. His pledge to honour Evonik's protection against compulsory redundancies until 2032 addresses employment concerns; it does not substitute for a commercial agreement between the two companies. Media reports suggest a higher offer could follow once the books have been examined, but that remains unconfirmed. Should BASF actually raise its bid, investors would have to weigh the improved price against the upside of a standalone Evonik that includes a possible US acquisition — and a higher offer only becomes a solid reference point once it is on the table.

A larger Evonik purchase could, in parallel, complicate a BASF takeover. That would not automatically create value. In the unfavourable scenario, one transaction becomes harder while the other is only available on unconvincing terms. Investors should not mistake a more difficult path for BASF as an economic gain.

Product News Is Not Yet Earnings

On the operating side, Evonik on Monday introduced Lypron, a rumen-stable lysine solution that extends its amino-acid balancing concept for ruminants. The launch broadens the offering; it does not amount to a proven contribution to results. The distinction between product progress and economic effect is the one that counts. A new product can improve the business outlook, but whether it forms a durable basis for valuation must show up in trading performance and company guidance.

That is why the 3 November quarterly report is the real test. A convincing set of figures and an outlook would strengthen confidence in Evonik's standalone development and reduce the investment case's reliance on the outcome of any takeover talks. Product launches could then be read as part of an economically coherent story rather than as headlines.

Politics and Labour Are Not Background Noise

The counter-image is a business performance that offers no convincing standalone perspective — in which case the takeover theme would carry more weight in valuation. Serious reservations exist there, and investors should not treat them as mere noise.

North Rhine-Westphalia's economics minister, Mona Neubaur, spoke out explicitly against a BASF takeover of Evonik in the state parliament on 14 October. In the same session, the parliament rejected an SPD motion seeking greater state influence. Political opposition to the deal and the rejection of additional state involvement sit side by side.

Labour has weighed in too. According to a Handelsblatt report dated 9 October, IG BCE chief Michael Vassiliadis questioned a full sale of the RAG-Stiftung's Evonik stake to BASF; the letter to works councils was dated 7 October. The RAG-Stiftung itself said on 9 October that its board of trustees had been briefed on BASF's takeover interest, without committing to the offer; Handelsblatt reported that Evonik and BASF should first negotiate bilaterally.

None of this proves a transaction will fail. It does argue against treating a sale as a secured valuation anchor. Weak operating signals combined with persistent objections to a takeover would be a particularly unfavourable combination.

What to Watch Next

As long as Evonik can underpin a credible standalone earnings outlook, the investment decision can rest more heavily on the business, with takeover considerations as an additional factor rather than the premise of the whole thesis. If confidence in operating development slips, the weight of a possible change of ownership rises — and investors would then have to factor in the political and labour headwinds as well. Interest in a takeover does not equal a deal.

The next concrete catalyst is the quarterly report on 3 November. It will not settle the takeover question by itself. What it will do is give investors the next checkpoint for judging how much economic substance the standalone Evonik story carries. A confirmed refinement of either track — purchase terms for Ashland or a revised BASF offer — would be the other trigger, and no date for either is confirmed. Until then, the news flow argues for separating negotiating possibilities from solid transaction values. What matters is not which route makes headlines first, but which can create value for Evonik shareholders on defensible terms.